Biomarker Profiling in Abdominal Aortic Aneurysm Patients

Launched by ERASMUS MEDICAL CENTER · Oct 9, 2018

Keywords

ClinConnect Summary

The BIOMArCS-AAA study is a clinical trial that aims to understand how certain blood markers might be related to the growth of abdominal aortic aneurysms (AAAs). An abdominal aortic aneurysm is a swelling in a major blood vessel in the abdomen, which can be serious if it grows too large. Researchers are particularly interested in how these blood markers might help predict outcomes for patients with AAA, especially those who have also experienced heart-related issues.

To participate in this study, you need to be at least 18 years old and have been diagnosed with an AAA that is 40mm or larger. You could be eligible if you are being monitored for your aneurysm, are planning to undergo a procedure called endovascular aneurysm repair (EVAR), or have already had this procedure in the past few years. If you join the study, you will have regular check-ups and blood tests to help researchers gather important information about your condition. This research is crucial for better understanding and managing AAA, and it could lead to improved care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age of 18 years or older
• • Capable of understanding and signing informed consent AND one of the following
• • 1. Diagnosis of AAA, with a diameter ≥40mm, based on any imaging technique and treated by watchful waiting strategy (Prospective longitudinal study, Arm 1 watchful waiting group)
• • 2. Planned to undergo EVAR for AAA (Prospective longitudinal study, Arm 2 EVAR group)
• • 3. Underwent EVAR for AAA in past years (Cross-sectional study)
• Exclusion Criteria:
• • Patients with isolated iliac artery aneurysm, traumatic aneurysm, anastomotic aneurysm and infectious aneurysm
• • Patients with a clinical diagnosed thoracic aneurysm (i.e. located in the chest, above the diaphragm)
• • Coexistent condition with life expectancy ≤ 1 year
• • Dialysis dependent, (end stage) renal disease patients
• • Women of childbearing age
• • Linguistic barrier
• • Unlikely to appear at all scheduled follow-up visits